SCHEDULE 13G/A: BlackRock Amends Stake in RAPT Therapeutics, Inc., Disclosing 1.7% Passive Ownership
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, reporting a 1.7% beneficial ownership stake in RAPT Therapeutics, Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 4 to its Schedule 13G, disclosing its beneficial ownership in RAPT Therapeutics, Inc.
- As of March 31, 2025, BlackRock, Inc. beneficially owned an aggregate of 2,306,622 shares of RAPT Therapeutics, Inc. Common Stock.
- This ownership represents 1.7% of the class of securities.
- BlackRock, Inc. holds sole voting power over 2,265,368 shares and sole dispositive power over 2,306,622 shares.
- No shared voting or dispositive power was reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing (Schedule 13G) disclosing passive ownership, which does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement (measurement date for ownership) |
| 04/25/2025 | Filing date of Schedule 13G Amendment No. 4 |
Keywords
BlackRock, RAPT Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.